Sodium valproate-induced Fanconi syndrome in two severely disabled patients receiving carnitine supplementation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

1. Kidney tubular injury induced by valproic acid: systematic literature review.Pediatric nephrology (Berlin, Germany) · 2023
   Pooled it
2. Reversible Secondary Carnitine Deficiency Associated With ChronicClinical medicine insights. Case reports · 2026
   Article
3. Combined effects of valproate and naringin on kidney antioxidative markers and serum parameters of kidney function in C57BL6 mice.Arhiv za higijenu rada i toksikologiju · 2023
   Article
4. Valproic-induced Fanconi syndrome: Clinical features, risk factors, diagnosis and management.Frontiers in medicine · 2022
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as